New drugs in acute myeloid leukemia

Annals of Oncology : Official Journal of the European Society for Medical Oncology
T M KadiaH Kantarjian

Abstract

The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications to the dose and schedule of existing agents have led to steady improvements in outcomes. However, developing new therapies for AML has been challenging. Although there have been advances in understanding the biology of AML, translating this knowledge to viable treatments has been slow. Active research is currently ongoing to address this important need and several promising drug candidates are currently in the pipeline. Here, we review some of the most advanced and promising compounds that are currently in clinical trials and may have the potential to be part of our future armamentarium. These drug candidates range from cytotoxic chemotherapies, targeted small-molecule inhibitors, and monoclonal antibodies.

References

Jul 10, 2007·Cancer Research·Christine B YooPeter A Jones
Jan 31, 2008·Journal of the National Cancer Institute·Weiguo ZhangMichael Andreeff
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco MandelliTheo de Witte
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop KantarjianWilliam Plunkett
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop M Kantarjian
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettKeith Wheatley
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanArthur C Louie
Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop M Kantarjian
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claude GardinHervé Dombret
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert ServeWolfgang E Berdel
Aug 3, 2013·Blood·Robertson Parkman
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roelof WillemzeTheo de Witte
Sep 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenRobert Soiffer

❮ Previous
Next ❯

Citations

Apr 25, 2018·Journal of Experimental & Clinical Cancer Research : CR·Branson ChenLi Zhang
May 30, 2019·Future Medicinal Chemistry·José Cjmds Menezes, Marc Diederich
Mar 10, 2020·Journal of Cellular and Molecular Medicine·Zuyi YangXiaohui Chen
Feb 28, 2020·Molecular & Cellular Proteomics : MCP·Carolien van AlphenConnie R Jimenez
Jun 8, 2018·Oncotarget·Aylin CamgozFrank Buchholz
Jul 1, 2017·Targeted Oncology·Maximilian StahlAmer M Zeidan
Feb 22, 2017·Journal of Hematology & Oncology·Hubert HacklRotraud Wieser
Mar 13, 2018·Physiological Research·V VenturiM Pospisek
Mar 25, 2019·Current Oncology Reports·Maximilian Stahl, Aaron D Goldberg
May 22, 2019·Journal of Translational Medicine·Bhuwan GiriAshok Saluja
Jan 11, 2020·Frontiers in Oncology·Raoul Tibes, James M Bogenberger
Jan 17, 2021·Molecular & Cellular Proteomics : MCP·Carolien van AlphenConnie R Jimenez
Feb 10, 2021·Journal of Proteomics·Carolien van AlphenJeroen J W M Janssen
Sep 18, 2018·Leukemia Research·Chetasi Talati, Kendra Sweet
Feb 8, 2018·Molecular Pharmaceutics·Alessia RomaPaul A Spagnuolo
Jun 15, 2016·Oncology Research·Gangcan LiJia Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.